493 related articles for article (PubMed ID: 1941528)
21. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
22. Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
Rougemont M; Nchotu Ngang P; Stoll B; Delhumeau C; Hill A; Ciaffi L; Bonnet F; Menga G; Fampou JC; Calmy A
HIV Med; 2016 Mar; 17(3):206-15. PubMed ID: 26354678
[TBL] [Abstract][Full Text] [Related]
23. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
24. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
[TBL] [Abstract][Full Text] [Related]
25. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women.
Melvin AJ; Burchett SK; Watts DH; Hitti J; Hughes JP; McLellan CL; King PD; Johnson EJ; Williams BL; Frenkel LM; Coombs RW
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):232-6. PubMed ID: 9117455
[TBL] [Abstract][Full Text] [Related]
26. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.
Rolinski B; Bogner JR; Sadri I; Wintergerst U; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jul; 15(3):192-7. PubMed ID: 9257653
[TBL] [Abstract][Full Text] [Related]
27. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
Easterbrook PJ; Emami J; Gazzard B
AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
[TBL] [Abstract][Full Text] [Related]
28. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.
Montaner JS; Singer J; Schechter MT; Raboud JM; Tsoukas C; O'Shaughnessy M; Ruedy J; Nagai K; Salomon H; Spira B
AIDS; 1993 Feb; 7(2):189-96. PubMed ID: 8466681
[TBL] [Abstract][Full Text] [Related]
29. [Frequency and characteristics of patients treated with zidovudine and absence of progression of HIV infection].
Soriano V; Heredia A; Mas A; Vallejo A; Garćia-Lerma G; Bravo R; Gómez-Cano M; Villalba N; Moreno V; Laguna F; Valencia E; Martínez P; González-Lahoz J
An Med Interna; 1997 Jun; 14(6):282-5. PubMed ID: 9410098
[TBL] [Abstract][Full Text] [Related]
30. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
Carr A; Vella S; de Jong MD; Sorice F; Imrie A; Boucher CA; Cooper DA
AIDS; 1996 Jun; 10(6):635-41. PubMed ID: 8780818
[TBL] [Abstract][Full Text] [Related]
31. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
32. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Ruiz L; Romeu J; Martínez-Picado J; Schmit JC; Vandamme AM; Balagué M; Cabrera C; Puig T; Tural C; Segura A; Sirera G; De Clercq E; Clotet B
AIDS; 1996 Dec; 10(14):F61-6. PubMed ID: 8970679
[TBL] [Abstract][Full Text] [Related]
34. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
35. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group.
Bhadrakom C; Simonds RJ; Mei JV; Asavapiriyanont S; Sangtaweesin V; Vanprapar N; Moore KH; Young NL; Hannon WH; Mastro TD; Shaffer N
AIDS; 2000 Mar; 14(5):509-16. PubMed ID: 10780713
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
[TBL] [Abstract][Full Text] [Related]
37. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
Pakker NG; Kroon ED; Roos MT; Otto SA; Hall D; Wit FW; Hamann D; van der Ende ME; Claessen FA; Kauffmann RH; Koopmans PP; Kroon FP; ten Napel CH; Sprenger HG; Weigel HM; Montaner JS; Lange JM; Reiss P; Schellekens PT; Miedema F
AIDS; 1999 Feb; 13(2):203-12. PubMed ID: 10202826
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
;
AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
[TBL] [Abstract][Full Text] [Related]
39. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.
Sperber K; Chiang G; Chen H; Ross W; Chusid E; Gonchar M; Chow R; Liriano O
Clin Ther; 1997; 19(5):913-23. PubMed ID: 9385480
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
